Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility. The biotech is outlicensing ...
Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the ...
- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - ...
Maximizing opportunities for its proprietary ARCUS genome editing platform was among the priorities Precision BioSciences articulated last fall when it named veteran biotech executive Michael Amoroso ...
News-Medical.Net on MSN
New method can help better assess precision genome editing technology
Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.
DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Most genetic variants that contribute to disease are challenging to correct efficiently and without excess byproducts in therapeutically relevant cell types using programmable nucleases. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback